Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective study
The addition of toripalimab to GP induction chemotherapy significantly improves EFS without increasing toxicity in LANPC.
Authors
- Jianghu Zhang (ORCID: https://orcid.org/0000-0001-9551-9347)
- Zhanmei Wang
- Renba Liang (ORCID: https://orcid.org/0000-0001-5050-8847)
- Fangmeng Fu (ORCID: https://orcid.org/0000-0002-3065-5708)
- Xinxiao Li (ORCID: https://orcid.org/0000-0002-4899-9832)
- Peng Chen (ORCID: https://orcid.org/0000-0002-1536-4945)
- Jing Jin (ORCID: https://orcid.org/0000-0002-6645-5214)
- Li Ma (ORCID: https://orcid.org/0000-0001-7785-2007)
- Ling Lei (ORCID: https://orcid.org/0009-0007-4404-3431)
- Teng Zou
- Fengming Lan
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- Shenzhen Luohu People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-24
- DOI
- https://doi.org/10.3389/fonc.2025.1704442
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- Sanming Project of Medicine in Shenzhen